The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation.

Therapeutic advances in treating patients with multiple myeloma (MM), including novel immunotherapies, have improved the disease control, but it remains incurable. Although traditional immune check point inhibitors have shown limited clinical benefit, targeting alternative immune-inhibitory pathways may offer a novel way to address relapsed disease. Blockade of the immune regulator TIGIT was shown to enhance anti-tumor immunity in preclinical MM models.

Primary inferior vena cava synovial sarcoma treated with caval replacement during cardiopulmonary bypass and liver perfusion.

Primary inferior vena cava (IVC) tumors are rare. Most are leiomyosarcomas. The prognosis is poor with those involving and superior to the hepatic veins faring worse than those isolated within the retrohepatic cava.

[CANCER SURVIVORS - QUESTIONS, CONSIDERATIONS AND POSSIBLE SOLUTIONS].

Objectives: To describe and evaluate the gaps in cancer survivors' treatment in Israel and suggest possible methods of meeting their needs.

Methods: This narrative review explores cancer survivors' unmet needs and global methodologies aiming at meeting them within various health systems.

Results: Cancer survivorship has become a topic of great interest in the past few years.

Dual-energy subtraction radiography (DESR): a systematic review and meta-analysis of pulmonary nodule detection.

Purpose: This study examined the literature to compare the accuracy, sensitivity, and specificity of dual-energy subtraction radiography (DESR) with conventional radiography (CR) in the detection of pulmonary nodules. To our knowledge, no meta-analysis has been conducted to compare DESR with CR.

Material And Methods: The authors searched Pubmed using the terms "Dual-energy subtraction radiography," and "Dual-Energy Chest Radiography.